Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination

Pulmonary Pharmacology and Therapeutics

Volumn 19, Issue 6, 2006, Pages 419-424

  Brown, Rachel A ^a   Allegra, Luigi ^b   Matera, Maria G ^c   Page, Clive P ^a   Cazzola, Mario ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d CARDARELLI HOSPITAL   (Italy)

Author keywords

Clinical trial; COPD; Enoxaparin; Heparin

Indexed keywords

ENOXAPARIN; FLUTICASONE PROPIONATE; LOW MOLECULAR WEIGHT HEPARIN; SALBUTAMOL; SALMETEROL;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD GAS TENSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEMATOMA; HUMAN; INJECTION SITE REACTION; LUNG FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

AGED; ALBUTEROL; ANDROSTADIENES; ANTICOAGULANTS; BLOOD GAS ANALYSIS; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSPNEA; ENOXAPARIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; VITAL CAPACITY;

EID: 33747236185     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2006.04.004     Document Type: Article

References (25)

1. McLean J. The thromboplastic action of cephalin. Am J Physiol 41 (1916) 250
2. Parish R., Coombe D.R., Jakobsen K.B., Bennett F.A., and Underwood P.A. Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases. Int J Cancer 40 (1987) 511-518
3. Tyrell D.J., Horne A.P., Holme K.R., Preuss J.M.H., and Page C.P. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 46 (1999) 151-208
4. Lever R., and Page C.P. Novel drug development opportunities for heparin. Nat Rev Drug Discov 1 (2002) 140-148
5. Page C.P. One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by beta 2-agonists. Lancet 337 (1991) 717-720
6. Parsons C.L. Current strategies for managing interstitial cystitis. Expert Opin Pharmacother 5 2 (2004) 287-293
7. Redini F., Tixier J.-M., Petitou M., Choay J., Robert L., and Hornebeck W. Inhibition of leucocyte elastase by heparin and its derivatives. Biochem J 252 (1988) 515-519
8. Rao N.V., Kennedy T.P., Rao G., Ky N., and Hoidal J.R. Sulfated polysaccharides prevent human leukocyte elastase-induced acute lung injury and emphysema in hamsters. Am Rev Respir Dis 142 (1990) 407-412
9. Lafuma C., Frisdal E., Harf A., Robert L., and Hornebeck W. Prevention of leucocyte elastase-induced emphysema in mice by heparin fragments. Eur Respir J 4 (1991) 1004-1009
10. Walsh R.L., Dillon T.J., Scicchitano R., and McLennan G.B. Heparin and heparan sulphate are inhibitors of human leucocyte elastase. Clin Sci 81 (1991) 341-346
11. Brown R.A., and Page C.P. The effects of unfractionated heparin and related molecules upon neutrophil-induced injury to human bronchial epithelial cells. Am J Respir Crit Care Med 169 (2004) A809
12. Ledoux D., Merciris D., Barritault D., and Caruelle J.P. Heparin-like dextran derivatives as well as glycosaminoglycans inhibit the enzymatic activity of human cathepsin G. FEBS Lett 537 (2003) 23-29
13. Ramdin L., Perks B., Sheron N., and Shute J.K. Regulation of interleukin-8 binding and function by heparin and alpha2-macroglobulin. Clin Exp Allergy 28 (1998) 616-624
14. Lever R., Hoult J.R., and Page C.P. The effects of heparin and related molecules upon the adhesion of polymorphonuclear leukocytes to vascular endothelium in vitro. Br J Pharmacol 129 (2000) 533-540
15. Salas A., Sans M., Soriano A., Reverter J.C., Anderson D.C., Pique J.M., et al. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 47 (2000) 88-96
16. Xie X., Rivier A.S., Zakrzewicz A., Bernimoulin M., Zeng X.L., Wessel H.P., et al. Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides. Studies with carboxyl-reduced and sulfated heparin and with trestatin a sulfate. J Biol Chem 275 (2000) 34818-34825
17. Wan M.X., Liu Q., Wang Y., and Thorlacius H. Protective effect of low molecular weight heparin on experimental colitis: role of neutrophil recruitment and TNF-alpha production. Inflamm Res 51 (2002) 182-187
18. Jones H., Paul W., and Page C.P. The effects of heparin and related molecules on vascular permeability and neutrophil accumulation in rabbit skin. Br J Pharmacol 135 (2002) 469-479
19. Brown R.A., Lever R., Jones N., and Page C.P. Effects of heparin and related molecules upon neutrophil aggregation and elastase release in vitro. Br J Pharmacol 139 4 (2003) 845-853
20. American Thoracic Society. Standardisation of spirometry. Am Rev Respir Dis 136 (1987) 1285-1298
21. Cazzola M., Di Lorenzo G., Di Perna F., Calderaro F., Testi R., and Centanni S. Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest 118 (2000) 1576-1581
22. Bendstrup K.E., Gram J., and Jensen J.I. Effect of inhaled heparin on lung function and coagulation in healthy volunteers. Eur Respir J 19 4 (2002) 606-610
23. Alessandri C., Basili S., Violi F., Ferroni P., Gazzaniga P.P., and Cordova C. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic obstructive bronchitis and haemostasis group. Thromb Haemost 72 3 (1994) 343-346
24. Fryer A., Huang Y.C., Rao G., Jacoby D., Mancilla E., Whorton R., et al. Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther 282 (1997) 208-219
25. Bavington C.D., Lever R., Mulloy B., Grundy M.M., Page C.P., Richardson N.V., et al. Anti-adhesive glycoproteins in echinoderm mucus secretions. Comp Biochem Physiol B Biochem Mol Biol 139 4 (2004) 607-617